Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Optibrium Launches SentiraTM: New Software for Compound Data Visualisation

Published: Monday, August 11, 2014
Last Updated: Monday, August 11, 2014
Bookmark and Share
Powerful desktop application simplifies visualisation, interpretation and presentation of compound data.

Optibrium today announced the launch of Sentira™, a new desktop application that provides dynamic data visualisation and analysis of compound data. Applicable across all fields of chemistry, Sentira enables users to quickly find patterns in compound data, visualise structure-activity relationships (SAR) and elegantly present and report findings. Researchers can intuitively review and interpret compound data sets from large screening libraries to individual chemical series in drug discovery, agrochemical, flavourings, cosmetics, fragrances and other industries.

Sentira provides a comprehensive range of plots, all with extensive and fully customisable features. Multiple plots can be created side-by-side, all dynamically linked to each other and the underlying data set, enabling quick identification of important relationships between compound properties. Flexible tools for SAR and matched pair analysis, coupled with a link to the underlying compound structures, affords insightful and intelligent compound data analysis.

Sentira’s simple design and user-friendly environment provides data management tools to perform calculations, merge, sort, filter and tag data sets, and import and export industry standard file formats on Mac or PC. Sentira also makes it easy to professionally present the results of analyses in presentations and reports.

Available for download from www.sentira-software.com, users can immediately get started with a free 30-day trial. Following this, flexible and cost-effective Sentira licensing options are available, including monthly, annual and perpetual plans.
Sentira is a new addition to Optibrium’s portfolio of products, which also includes: StarDrop™, a flagship platform that provides comprehensive capabilities for the design and selection of high quality compounds; and Asteris™, an iPad® app that enables interactive compound design and predictive modelling, wherever and whenever it’s required.

Dr Matthew Segall, Optibrium’s CEO, commented “We recognised the need for a user-friendly, yet powerful, compound data visualisation application at a reasonable price. By leveraging the development that we had already undertaken in StarDrop, we are pleased to be able to offer such a solution as part of our expanded range of software products.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Optibrium and Certara Collaborate
Collaboration will see integration of Optibrium’s StarDrop and Certera’s D360 platform.
Tuesday, April 21, 2015
Optibrium and ChemAxon Collaborate
Interface between StarDrop and Plexus facilitates seamless access to both software platforms.
Wednesday, April 15, 2015
Scientific News
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Visualizing a Cancer Drug Target at Atomic Resolution
Using cryo-electron microscopy, researchers were able to view, in atomic detail, the binding of a potential small molecule drug to a key protein in cancer cells.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
Biomarker for Recurring HPV-Linked Oropharyngeal Cancers
A look-back analysis of HPV infection antibodies in patients treated for oropharyngeal (mouth and throat) cancers linked to HPV infection suggests at least one of the antibodies could be useful in identifying those at risk for a recurrence of the cancer, say scientists at the Johns Hopkins University.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Light Signals from Living Cells
Fluorescent protein markers delivered under high pressure.
Cellular 'Relief Valve'
A team led by scientists at The Scripps Research Institute (TSRI) has solved a long-standing mystery in cell biology by showing essentially how a key “relief-valve” in cells does its job.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!